Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit inks breakthrough Seglin deal with Bristol-Myers Squibb

  Summit Corp this morning unveiled a collaboration with one of the world’s largest pharmaceuticals companies that could eventually be worth US$30 million per product in research, development and regulatory milestone payments.  
Summit inks breakthrough Seglin deal with Bristol-Myers Squibb

 

Summit Corp (LON:SUMM) this morning unveiled a collaboration with one of the world’s largest pharmaceuticals companies that could eventually be worth US$30 million per product in research, development and regulatory milestone payments.

Initially Bristol-Myers Squibb will pay US$100,000 fee to access the company’s Seglin technology.

It is hoped these second generation immunosugars will provide a radical new platform to develop drugs for illnesses such as Alzheimers. 

The importance of proteins and nucleic acids is well established in drug discovery, but the targeting of carbohydrate biology remains largely underexploited.  Seglin technology hopes to redress the balance. 

The partnership is an early first step in the re-focused strategy set out by chief executive Glyn Edwards.

Last week he revealed he wanted “someone else to pick up the heavy lifting” on the exciting Seglin programme, which is still in the very early phase of development, to allow the company to focus on their two key drug candidates.

In C1100, the group has a potentially breakthrough treatment for Duchenne Muscular Dystrophy. Its second major discovert, SMT 19969, is a highly potent anti-biotic designed to tackle the hospital superbug C.difficile.

Edwards said this morning: “This agreement with Bristol-Myers Squibb further reinforces our strategy as we seek alternative ways to realise the value of our Seglin technology while we concentrate our resources on advancing our core Duchenne Muscular Dystrophy and C. difficile programmes.”

Under the terms of the agreement, Bristol-Myers will be responsible for the discovery stage research and will have the exclusive right to develop and commercialise any Seglin products that are identified.

The AIM listed group will receive afore mentioned technology access fee and is eligible for research, development and regulatory milestones of up to $30 million per product, plus royalties on worldwide sales of any products. 


 

Ian_55ae0ddd437b7.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile

Summit Therapeutics PLC Timeline

Related Articles

1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
knee_5672a90cad559.jpg
December 17 2015
Put simply, Tissue Regenix takes a tendon or cartilage – either from a human or from a pig – treats it and uses it to replace damaged tissue within the body.
rsz_shutterstock_118277080.jpg
January 19 2016
Horizon Discovery is a machine, which keeps motoring, underlined by the life sciences group's positive update on 2015 trading.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.